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with COPDTo the Editor,
We read the work by Sabit and co-workers1 on the
subclinical ventricular dysfunction in patients with chronic
obstructive pulmonary disease (COPD). In this study the
right ventricular dysfunction seems to be related to the
severity of airways obstruction.
COPD is increasingly recognized as a respiratory disease
with an important systemic component.2 The degrees of
hypoxemia, pulmonary hypertension, and the inflammatory
response on presentation to the emergency department as
well as underlying comorbidities and the extent of cardiac
stress have all been described as adverse prognostic factors
in patients with an acute exacerbation of COPD.3
B-type natriuretic peptide (BNP), a 32-amino-acid poly-
peptide, is released predominately by the left and right
cardiac ventricles and regulates a wide array of physiologic
effects including natriuresis, diuresis, and vasodilatation.4
The main stimulus for the secretion of BNP is cardiac
stress reflected by myocardial stretch and pressure or
volume overload. Recent evidence also suggests that BNP
levels summarize and integrate the extent of left ventric-
ular systolic dysfunction, left ventricular diastolic
dysfunction, valvular dysfunction, and right ventricular
dysfunction.5,6
We would like to briefly report preclinical data of our
study to evaluate the use of BNP to predict right ventricular
dysfunction in patients with acute exacerbation COPD.
Materials and methods
The study was conducted in the Emergency Department of
the Fatebenefratelli Hospital (Milan, Italy). Informed
consent was obtained from all participating patients.
In total, 39 consecutive patients (20 male gender, 79  9
age yr) with acute dyspnoea were enrolled in the study.
Patients with renal failure or with malignancy were care-
fully excluded.
Each subject provided medical information, physical
examination, blood tests, chest X-ray, arterial blood gas0954-6111/$ - see front matter ª 2010 Elsevier Ltd. All rights reserved
doi:10.1016/j.rmed.2010.09.010analysis and echocardiography as well as plasma pro-BNP
levels were measured from fresh peripheral blood in 1.5 mg/
mL EDTA-1Na using an immuno-enzymometric assay kit.
Patients were categorized into two groups: A group (#17,
8 male gender, 81  8 age yr) included patients with
ventricular systolic dysfunction; B group (#22, 12 male
gender, 78  9 age yr) included acute exacerbation COPD
patients.
Results
No significant difference was found (A vs B) for age, gender,
and blood gas analysis values. Pro-BNP values were
increased in overall population, with a significant differ-
ence for A group (A group 9514  10360 pg/dl vs B group
2414  2399 pg/dl; p Z 0.004).
At the echocardiography pulmonary arterial systolic
pressure (PAPs) value was increased in the B group
(36.2  12.9 vs 34.5  7.2 mm Hg) as well as the left
ventricular ejection fraction (LVEF) (B group 57.4  14% vs
A group 49.2  13.3%). For both measures the difference
was not significant (p Z NS). A significant correlation
between pro-BNP value and PAPs was found in the B group
only (Spearman rank correlation r Z 0.43; p < 0.05).
Conclusions
Plasma BNP is a useful noninvasive biomarker for the
diagnosis and monitoring of cardiac diseases and heart
failure.7,8
In addition, it is well known that plasma BNP levels are
elevated in patients with secondary pulmonary hyperten-
sion and chronic lung disease with right ventricular
overload.9e11
Our results have shown that increased BNP values can be
found during acute exacerbations of COPD and can be
related to Pulmonary Artery Pressure. The BNP assay in
isolation was not found to be sufficient to discriminate
between cardiogenic and pulmonary dyspnoea.
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